LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY. Company management is scheduled to participate in a 30-minute question-and-answer session with the host ana ...

LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ...

Core Insights - Trinity Capital Inc. has committed $45 million in growth capital to Rapid Micro Biosystems, a company specializing in automation solutions for microbial quality control in healthcare product manufacturing [1][3][5] - Rapid Micro's Growth Direct platform enhances operational efficiency and data integrity, enabling faster and more accurate results in critical applications such as environmental monitoring and sterility testing [2][5] Company Overview - Trinity Capital Inc. is an alternative asset manager focused on private credit markets, having deployed over $4.7 billion across more than 420 investments since its inception in 2008 [4] - Rapid Micro Biosystems provides automation solutions that modernize manual microbial quality control testing workflows, significantly impacting biopharma manufacturing processes [5] Strategic Goals - The new capital from Trinity Capital will support Rapid Micro's global expansion of the Growth Direct platform and drive gross margin improvements through cost reductions and increased manufacturing efficiencies [3][4] - Rapid Micro aims to strengthen its financial position and focus on long-term revenue growth, margin expansion, and shareholder value enhancement [4]

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Summary of Rapid Micro Biosystems FY Conference Call Company Overview - **Company**: Rapid Micro Biosystems (NasdaqCM: RPID) - **Industry**: Biotechnology, specifically focusing on microbial quality control in pharmaceutical manufacturing Core Points and Arguments - **Market Focus**: Rapid Micro Biosystems is dedicated to improving microbial quality control processes in the pharmaceutical, biologics, medical devices, and personal care products sectors, aiming to modernize a method that has been in use for over 150 years [4][5] - **Revenue Performance**: In 2024, the company reported $28 million in revenue, reflecting a 25% growth rate, with over half ($15 million) coming from recurring revenue [5][6] - **Installed Base**: The company has placed approximately 170 systems globally, with over 150 validated, indicating strong market penetration [7][8] - **Customer Base**: Rapid Micro is engaged with 75% of the top 20 global biopharma companies and 86% of approved CAR T companies, highlighting its relevance in high-volume testing environments [9] - **Financial Growth**: The company has achieved a compound annual growth rate (CAGR) of 28% over recent years and aims for a growth rate of 25-30% moving forward [9][10] - **Gross Margins**: The company transitioned from negative gross margins of -55% in 2022 to breaking even in 2024, with expectations to reach around 50% by 2027 [10][11] Strategic Partnerships - **Merck Partnership**: A significant partnership with Merck includes co-exclusive distribution rights, allowing Merck to sell Rapid Micro's systems and consumables globally, which is expected to enhance growth and market reach [12][14] - **Supply Chain Benefits**: The partnership also aims to improve supply chain efficiencies and innovation through collaboration on consumable products [15][16] Technology and Innovation - **GrowthDirect Platform**: The company offers a fully automated system for microbial testing, which enhances data integrity and operational efficiency, significantly reducing testing times compared to traditional methods [22][25] - **Market Opportunity**: The total addressable market for transitioning the global pharmaceutical market to Rapid Micro's technology is estimated at $10 billion, with half attributed to hardware and half to recurring consumables [30][41] Industry Trends and Tailwinds - **Regulatory Environment**: Increasing regulatory scrutiny on manual methods is driving demand for automated solutions, as regulators are implementing stricter rules that necessitate more labor-intensive processes [30][31] - **Complex Biologics**: The rise of cell and gene therapies and complex biologics is creating a need for faster testing solutions, which Rapid Micro's technology can provide [31][32] - **Manufacturing Capacity Investments**: Significant investments in manufacturing capacity in the U.S. are expected to create additional demand for Rapid Micro's solutions [32] Growth Strategy - **Customer Acquisition**: The company aims to acquire new customers, particularly in biopharma and CDMO sectors, while also expanding within existing customer sites [33][35] - **Geographic Expansion**: Rapid Micro is focusing on increasing its footprint in Asia, alongside its established presence in North America and Europe [36] - **New Products and Services**: The introduction of new systems and software, such as Storility and MobileArm, is part of the strategy to drive revenue growth [37][38] Conclusion - **Market Position**: Rapid Micro Biosystems is well-positioned in a growing market with strong barriers to entry and a first-mover advantage in fully automated microbial quality control technology [41][42] - **Recurring Revenue Model**: The company expects to maintain over 50% of its revenue from recurring sources, with significant pull-through revenue per system [45][46]

Company Overview - Rapid Micro Biosystems, Inc. is an innovative life sciences technology company focused on providing automation solutions for the efficient manufacturing and safe release of healthcare products [3] - The company is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands [3] Product and Technology - The flagship product, Growth Direct system, automates microbial quality control (MQC) testing workflows, modernizing traditional manual processes in pharmaceutical manufacturing [3] - The Growth Direct system enhances operational efficiency, accuracy, compliance with data integrity regulations, and decision-making speed, ensuring a consistent supply of healthcare products [3] Upcoming Events - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025, at 11:00 a.m. ET [2] - A live webcast of the presentation will be available on the company's investor relations website and will be archived for replay [2]

**FORM 10-Q Filing Information** [**Registrant Information**](index=1&type=section&id=Registrant%20Information) Provides basic identification details of Rapid Micro Biosystems, Inc. as the registrant for the Form 10-Q filing for the quarterly period ended June 30, 2025, including its state of incorporation, principal executive offices, telephone number, and SEC file number, confirming compliance with SEC filing requirements and identifying the company as a non-accelerated filer, smaller reporting company, and emerging growth company - Registrant: Rapid Micro Biosystems, Inc[2](index=2&type=chunk) - Filing Period: Quarterly period ended June 30, 2025[2](index=2&type=chunk) - SEC File Number: 001-40592[2](index=2&type=chunk) Registrant Status | Status | Indication | | :------------------------ | :--------- | | Large accelerated filer | o | | Accelerated filer | o | | Non-accelerated filer | x | | Smaller reporting company | x | | Emerging growth company | x | - Outstanding Shares as of August 8, 2025: Class A common stock: **39,710,799 shares**; Class B common stock: **4,499,529 shares**[6](index=6&type=chunk) **TABLE OF CONTENTS** **FORWARD-LOOKING STATEMENTS** [**Safe Harbor and Identification**](index=3&type=section&id=Safe%20Harbor%20and%20Identification) States that the Quarterly Report on Form 10-Q contains forward-looking statements intended to be covered by safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934, identifiable by terms like 'may,' 'will,' 'expects,' and 'plans,' based on current expectations and projections about future events and financial trends - Forward-looking statements are covered by safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act[11](index=11&type=chunk) - Identifiable by terms such as 'may,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'could,' 'intends,' 'targets,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'forecasts,' 'predicts,' 'potential' or 'continue' or their negatives[11](index=11&type=chunk) [**Key Forward-Looking Statements and Risks**](index=3&type=section&id=Key%20Forward-Looking%20Statements%20and%20Risks) Forward-looking statements include expectations regarding the Growth Direct platform, future financial results (revenue, gross margin, operating expenses, cash flow), the goal of achieving positive cash flow by end of 2027, impact of new debt facility, funding requirements, customer base expansion, R&D activities, and intellectual property protection, which are subject to known and unknown risks, uncertainties, and important factors, particularly those discussed in the 'Risk Factors' section - Forward-looking statements include business strategy for Growth Direct platform, future results of operations and financial position (revenue, gross margin, operating expenses, positive cash flow), and the goal to achieve positive cash flow by end of 2027[13](index=13&type=chunk) - Also covers expected impact of the recently-announced debt facility, future funding requirements, ability to maintain and expand customer base, effectiveness of sales force, anticipated market trends, R&D activities, and intellectual property protection[13](index=13&type=chunk) - Caution: Actual results, performance, or achievements may differ materially due to known and unknown risks, uncertainties, and other important factors, including those in Part II, Item 1A, 'Risk Factors'[12](index=12&type=chunk) **SUMMARY RISK FACTORS** [**Principal Risks and Uncertainties**](index=4&type=section&id=Principal%20Risks%20and%20Uncertainties) Provides a concise overview of the primary risks and uncertainties affecting the company's business, including significant historical losses and expected future losses, challenges in achieving and maintaining positive cash flow, dependence on the commercial success of the Growth Direct platform, and potential fluctuations in operating results, along with other risks such as the need for additional capital, indebtedness, market competition, new product development complexities, regulatory compliance, inventory management, and intellectual property protection - Incurred significant losses since inception and expects future losses; may not achieve positive cash flow and profitability[16](index=16&type=chunk) - Business relies on the commercial success of the Growth Direct platform, which may not be achieved or maintained[16](index=16&type=chunk) - Operating results have fluctuated and will continue to fluctuate, making future results difficult to predict[16](index=16&type=chunk) - May need to raise additional capital; existing and future indebtedness could adversely affect operations[16](index=16&type=chunk) - Challenges include maintaining market position, expanding customer base, timely new product development, managing inventory, and competing successfully[16](index=16&type=chunk)[21](index=21&type=chunk) - Risks also involve potential product liability lawsuits, loss of key management, manufacturing facility damage, reliance on third-party suppliers, and intellectual property protection issues[21](index=21&type=chunk) **TRADEMARKS** [**Trademark Usage Disclaimer**](index=5&type=section&id=Trademark%20Usage%20Disclaimer) Clarifies that trademarks and trade names in the report are referred to without ® and ™ symbols for convenience, but this should not be interpreted as a waiver of the company's full legal rights to these marks - Trademarks and trade names are used without ® and ™ symbols for convenience[18](index=18&type=chunk) - Such references do not indicate a waiver of the company's full rights under applicable law[18](index=18&type=chunk) **INTERNET POSTING OF INFORMATION** [**Investor Information Access**](index=5&type=section&id=Investor%20Information%20Access) The company routinely posts important investor information in the 'Investors' section of its website, www.rapidmicrobio.com, and encourages investors to consult it regularly, noting that the website content is not incorporated by reference into this Form 10-Q - Important investor information is routinely posted in the 'Investors' section of www.rapidmicrobio.com[20](index=20&type=chunk) - Website content is not incorporated by reference into this Form 10-Q[20](index=20&type=chunk) **Part I — Financial Information** [**Item 1. Financial Statements**](index=6&type=section&id=Item%201.%20Financial%20Statements) Presents the unaudited condensed consolidated financial statements for Rapid Micro Biosystems, Inc., including the balance sheets, statements of operations, comprehensive loss, stockholders' equity, and cash flows, along with detailed notes explaining the company's business, accounting policies, financial instruments, and other relevant financial information for the periods ended June 30, 2025, and December 31, 2024 [**Condensed Consolidated Balance Sheets**](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The condensed consolidated balance sheets show a decrease in total assets and stockholders' equity from December 31, 2024, to June 30, 2025, primarily driven by a reduction in short-term investments and an increase in accumulated deficit Condensed Consolidated Balance Sheets (Unaudited, In thousands) | Item | June 30, 2025 | December 31, 2024 | | :---------------------------------- | :------------ | :------------------ | | **Assets** | | | | Cash and cash equivalents | $18,333 | $16,911 | | Short-term investments | $12,922 | $33,821 | | Total current assets | $60,146 | $80,917 | | Total assets | $75,586 | $98,169 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $16,403 | $17,565 | | Total liabilities | $21,041 | $22,817 | | Accumulated deficit | $(498,395) | $(475,274) | | Total stockholders' equity | $54,545 | $75,352 | - **Total assets** decreased by **$22,583 thousand** (**23.0%**) from December 31, 2024, to June 30, 2025[23](index=23&type=chunk) - **Total stockholders' equity** decreased by **$20,807 thousand** (**27.6%**) over the same period, largely due to an increased **accumulated deficit**[23](index=23&type=chunk) [**Condensed Consolidated Statements of Operations**](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The condensed consolidated statements of operations show an increase in total revenue for both the three and six months ended June 30, 2025, compared to the prior year, while **net loss** decreased, indicating improved operational efficiency Condensed Consolidated Statements of Operations (Unaudited, In thousands) | Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :----------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Product revenue | $4,802 | $4,537 | $8,903 | $8,250 | | Service revenue | $2,460 | $2,081 | $5,564 | $3,979 | | Total revenue | $7,262 | $6,618 | $14,467 | $12,229 | | Total costs and operating expenses | $19,410 | $19,996 | $38,276 | $39,880 | | Loss from operations | $(12,148) | $(13,378) | $(23,809) | $(27,651) | | Net loss | $(11,858) | $(12,578) | $(23,121) | $(25,900) | | Net loss per share

Core Insights - Rapid Micro Biosystems, Inc. reported a quarterly loss of $0.27 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.26, but an improvement from a loss of $0.29 per share a year ago [1] - The company posted revenues of $7.26 million for the quarter, missing the Zacks Consensus Estimate by 0.52%, but showing growth from $6.62 million in the same quarter last year [2] - The stock has increased by approximately 262.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The earnings outlook for Rapid Micro Biosystems is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.25 on revenues of $9.1 million, and for the current fiscal year at -$0.98 on revenues of $33.1 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Rapid Micro Biosystems belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 increased by 10% year-over-year to $7,300,000, slightly above the midpoint of guidance [7][16] - Recurring revenue rose by 15% to $4,400,000, driven by growth in consumables and service contracts [17] - Gross margins improved to 4%, a seven percentage point increase from the prior year, marking the fourth consecutive quarter of positive gross margins [8][17] Business Line Data and Key Metrics Changes - Product revenue increased by 6% to $4,800,000, supported by mid-teens growth in consumables and higher software sales [16] - Service revenue grew by 18% to $2,500,000, attributed to higher field service activity and increased contract revenue [17] - Four GrowthDirect systems were placed in Q2, maintaining guidance despite delays in customer site readiness [8][16] Market Data and Key Metrics Changes - The company is well-positioned to benefit from significant investments in new pharmaceutical manufacturing capacity in the US, which is expected to incorporate advanced technologies [11][12] - Global trade dynamics are creating uncertainty in customer purchase decisions, particularly for larger capital investments [11][12] Company Strategy and Development Direction - The company announced a new $45,000,000 term loan facility to support long-term strategy and positive cash flow [6][7] - The partnership with MilliporeSigma is expected to enhance product innovation and gross margin expansion over the long term [9][10] - The company is focusing on operational improvements and cost reduction initiatives to drive gross margin expansion [13][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about ongoing industry trends and customer support for automation and new technologies [11][12] - There is cautious optimism regarding the timing and scale of customer purchase decisions due to global trade dynamics [12][21] - The company expects to finish the year toward the low end of its previous guidance range for system placements due to near-term uncertainties [19][20] Other Important Information - The company plans to participate in several industry events, including the annual PDA Micro Conference and PharmaLab Congress, to showcase the GrowthDirect platform [14] - The company expects to complete at least 18 validations in 2025, with at least three in Q3 [20] Q&A Session Summary Question: Impact of pharma delays on decision-making - Management noted mixed signals in pharma decision-making but remains encouraged by ongoing conversations and projects with existing customers [24][25] Question: System placements and market share in CAR T - The majority of installations are in existing facilities, but new builds are expected to increase automation and efficiency, benefiting the company [27][28] Question: Reasons for lower guidance on system placements - Management cited trade dynamics and near-term uncertainties as reasons for expecting to finish the year at the lower end of the guidance range [30][31] Question: Stability of consumable revenue growth - Management expects sequential growth in consumables revenue in Q3 and Q4, driven by new high-volume sites coming online [32][34] Question: Near-term levers for gross margin improvement - Focus areas include product cost reduction, procurement efficiencies, and manufacturing improvements, with significant progress expected [37][39] Question: Timing for onshoring initiatives - Management anticipates benefits from onshoring initiatives but noted that specific timing remains uncertain due to construction and equipment ordering dynamics [42][46] Question: Attitude differences between existing and potential customers - Existing customers tend to be more resilient and have ongoing projects, while new customers may be more cautious in the current environment [50][52]

[Second Quarter 2025 Financial Results Overview](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Results%20Overview) The company reported a 10% increase in total revenue to $7.3 million, driven by service and product growth, with gross margin improving to 4% and a new $45 million term loan facility secured [CEO Commentary and Business Highlights](index=1&type=section&id=CEO%20Commentary) CEO Robert Spignesi highlighted 10% total revenue growth, driven by service and product segments, and announced a new $45 million term loan facility - **Total revenue increased 10%**, driven by an **18% increase in Service revenue**. Product revenue increased by **6%**, led by mid-teens growth in consumables[3](index=3&type=chunk) - Announced a new five-year, **$45 million term loan facility**, with **$20 million funded upfront** with highly favorable terms, significantly strengthening the financial position[3](index=3&type=chunk) - Strategic priorities remain unchanged: delivering significant **long-term revenue growth**, **gross margin expansion**, and **shareholder value**[3](index=3&type=chunk) [Q2 2025 Key Financial Highlights](index=1&type=section&id=Q2%202025%20Key%20Financial%20Highlights) Total revenue grew 10% to $7.3 million, recurring revenue increased 15%, gross margin improved to 4%, and full-year guidance was reaffirmed Q2 2025 Key Financial Highlights | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | Change (%) | | :----- | :------ | :------ | :--------- | | Total Revenue | $7.3 | $6.6 | +10% | | Recurring Revenue | $4.4 | $3.8 | +15% | | Gross Margin | 4% | -3% | +7 ppts | - Enters into five-year, **$45 million term loan facility** with **$20 million funded at close**[9](index=9&type=chunk) - Reaffirms full-year 2025 total revenue guidance of **at least $32.0 million**[9](index=9&type=chunk) [Detailed Second Quarter 2025 Financial Performance](index=1&type=section&id=Detailed%20Second%20Quarter%202025%20Financial%20Performance) Q2 2025 saw total revenue increase 10% to $7.3 million, gross margin improve to 4%, operating expenses decrease 6%, and net loss narrow to $11.9 million [Revenue Breakdown](index=1&type=section&id=Revenue%20Breakdown) Total revenue increased 10% to $7.3 million, driven by 18% service revenue growth and 6% product revenue growth, with recurring revenue up 15% Q2 2025 Revenue Breakdown | Revenue Type | Q2 2025 (Millions) | Q2 2024 (Millions) | YoY Change (%) | | :----------- | :----------------- | :----------------- | :------------- | | Total Revenue | $7.3 | $6.6 | +10% | | Product Revenue | $4.8 | $4.5 | +6% | | Service Revenue | $2.5 | $2.1 | +18% | | Recurring Revenue | $4.4 | $3.8 | +15% | - The company placed **four new Growth Direct® systems** and completed **two customer system validations**, a decrease from the prior year[4](index=4&type=chunk) [Cost of Revenue and Gross Margin](index=1&type=section&id=Cost%20of%20Revenue%20and%20Gross%20Margin) Total cost of revenue increased 3% to $7.0 million, while gross margin significantly improved by 7 percentage points to positive 4% Q2 2025 Cost of Revenue and Gross Margin | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | YoY Change (%) | | :----- | :----------------- | :----------------- | :------------- | | Total Cost of Revenue | $7.0 | $6.8 | +3% | | Gross Margin | 4% ($0.3) | -3% (-$0.2) | +7 ppts | [Operating Expenses](index=1&type=section&id=Operating%20Expenses) Total operating expenses decreased 6% to $12.4 million, driven by reductions in R&D and sales and marketing, despite a rise in G&A Q2 2025 Operating Expenses Changes | Expense Type | Q2 2025 (Millions) | Q2 2024 (Millions) | YoY Change (%) | | :----------- | :----------------- | :----------------- | :------------- | | Total Operating Expenses | $12.4 | $13.2 | -6% | | General and Administrative | $6.079 | $5.818 | +4% | | Research and Development | $3.230 | $3.744 | -14% | | Sales and Marketing | $3.114 | $3.627 | -14% | [Net Loss and Cash Position](index=1&type=section&id=Net%20Loss%20and%20Cash%20Position) Net loss improved to $11.9 million, with loss per share at $0.27, and cash position stood at approximately $32 million Q2 2025 Net Loss Performance | Metric | Q2 2025 (Millions) | Q2 2024 (Millions) | | :----- | :------ | :------ | | Net Loss | -$11.9 | -$12.6 | | Net Loss per Share | -$0.27 | -$0.29 | - Cash, cash equivalents, short-term investments, and restricted cash totaled approximately **$32 million** as of June 30, 2025[7](index=7&type=chunk) [2025 Financial Outlook](index=1&type=section&id=2025%20Financial%20Outlook) The company reaffirmed its full-year 2025 total revenue guidance of at least $32.0 million [Full-Year Guidance](index=1&type=section&id=Full-Year%20Guidance) Rapid Micro Biosystems reaffirmed its full-year 2025 total revenue guidance of at least $32.0 million - The company is reaffirming its full-year 2025 total revenue guidance of **at least $32.0 million**[8](index=8&type=chunk) [Strategic Financial Initiatives](index=3&type=section&id=Strategic%20Financial%20Initiatives) The company secured a new five-year, $45 million term loan facility, with $20 million funded upfront and additional tranches contingent on milestones [New Term Loan Facility](index=3&type=section&id=New%20Term%20Loan%20Facility) A new five-year, $45 million term loan facility was secured, with $20 million funded at close and additional tranches tied to milestones - Entered into a five-year, **$45 million term loan facility** with Trinity Capital Inc[10](index=10&type=chunk) - Received **$20 million at close** through the first tranche, with access to **two additional tranches totaling $20 million** contingent on commercial and operational milestones[10](index=10&type=chunk) - A fourth tranche of **$5 million** is available at the lender's discretion[10](index=10&type=chunk) [Company Profile](index=3&type=section&id=Company%20Profile) Rapid Micro Biosystems is an innovative life sciences technology company providing automated microbial quality control solutions for healthcare product manufacturing [About Rapid Micro Biosystems](index=3&type=section&id=About%20Rapid%20Micro%20Biosystems) Rapid Micro Biosystems is an innovative life sciences technology company offering automated microbial quality control solutions for healthcare product manufacturing - Innovative life sciences technology company providing mission-critical automation solutions for efficient manufacturing and safe release of healthcare products[13](index=13&type=chunk) - The flagship **Growth Direct system** automates and modernizes manual microbial quality control (MQC) testing workflows[13](index=13&type=chunk) - Headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands[13](index=13&type=chunk) [Unaudited Condensed Consolidated Financial Statements](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The unaudited financial statements detail Q2 2025 operations, balance sheet, and cash position, showing improved net loss and changes in assets and liabilities [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) The statements show an improved net loss of $11.9 million for Q2 2025, with total revenue increasing to $7.3 million due to revenue growth Unaudited Condensed Consolidated Statements of Operations (in thousands) | Metric | Three Months Ended June 30, 2025 (Thousands) | Three Months Ended June 30, 2024 (Thousands) | Six Months Ended June 30, 2025 (Thousands) | Six Months Ended June 30, 2024 (Thousands) | | :-------------------- | :------------------------------- | :------------------------------- | :------------------------------- | :------------------------------- | | Product revenue | $4,802 | $4,537 | $8,903 | $8,250 | | Service revenue | $2,460 | $2,081 | $5,564 | $3,979 | | Total revenue | $7,262 | $6,618 | $14,467 | $12,229 | | Total costs and operating expenses | $19,410 | $19,996 | $38,276 | $39,880 | | Net loss | $(11,858) | $(12,578) | $(23,121) | $(25,900) | | Net loss per share | $(0.27) | $(0.29) | $(0.52) | $(0.60) | [Unaudited Condensed Consolidated Balance Sheets](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $75.6 million, total liabilities to $21.0 million, and stockholders' equity to $54.5 million as of June 30, 2025 Unaudited Condensed Consolidated Balance Sheets (in thousands) | Metric | June 30, 2025 (Thousands) | December 31, 2024 (Thousands) | | :-------------------- | :------------ | :---------------- | | Total current assets | $60,146 | $80,917 | | Total assets | $75,586 | $98,169 | | Total current liabilities | $16,403 | $17,565 | | Total liabilities | $21,041 | $22,817 | | Total stockholders' equity | $54,545 | $75,352 | [Unaudited Cash, Cash Equivalents and Investments](index=6&type=section&id=Unaudited%20Cash%2C%20Cash%20Equivalents%20and%20Investments) Cash, cash equivalents, and investments decreased to $31.3 million as of June 30, 2025, primarily due to reduced short-term investments Unaudited Cash, Cash Equivalents and Investments (in thousands) | Metric | June 30, 2025 (Thousands) | December 31, 2024 (Thousands) | | :-------------------- | :------------ | :---------------- | | Cash and cash equivalents | $18,333 | $16,911 | | Short-term investments | $12,922 | $33,821 | | Cash, cash equivalents and investments | $31,255 | $50,732 | [Other Information](index=3&type=section&id=Other%20Information) This section provides details on the Q2 2025 webcast, investor relations disclosure, forward-looking statements, and company contacts [Webcast Details](index=3&type=section&id=Webcast%20Details) A conference call was held on August 12, 2025, to discuss Q2 2025 financial results, with webcast access and replay available - The company hosted a conference call on **August 12, 2025, at 8:30 a.m. ET** to discuss its second quarter 2025 financial results[12](index=12&type=chunk) - The live call is accessible on the company's investor relations website and will be archived for **one year**[12](index=12&type=chunk) [Investor Relations Disclosure](index=3&type=section&id=Investor%20Relations%20Disclosure) The company uses its Investor Relations page for disclosing material nonpublic information and fulfilling Regulation FD obligations - Rapid Micro Biosystems intends to use its Investor Relations page for disclosing material nonpublic information and complying with Regulation FD obligations[14](index=14&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section outlines forward-looking statements regarding future performance, including revenue guidance and cash flow, and details associated risks and uncertainties - Includes forward-looking statements on **full-year 2025 total revenue guidance**, Growth Direct placements, **cash flow breakeven**, debt facility impact, cost reduction, and product innovation[15](index=15&type=chunk) - Forward-looking statements involve inherent risks and uncertainties, including achieving **positive cash flow**, meeting business objectives, managing **significant losses**, debt obligations, market competition, technological changes, supply chain disruptions, and macroeconomic factors[16](index=16&type=chunk)[17](index=17&type=chunk) [Contacts](index=4&type=section&id=Contacts) Contact information is provided for investor relations and media inquiries - Investor Contact: **Michael Beaulieu, CFA**, Vice President, Investor Relations and Corporate Communications, investors@rapidmicrobio.com[18](index=18&type=chunk) - Media Contact: media@rapidmicrobio.com[18](index=18&type=chunk)